Condition
Immunosuppressive Agents clinical trials and research
As of November 12, 2026, Find a Trial lists 2 Immunosuppressive Agents clinical trials that are recruiting, at sites in 2 countries (most in France (1), Italy (1)). By phase: Phase 4 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 2Countries
All recruiting trials (2)
-
Education on Immunosuppressive Therapy Reduction in Kidney Transplant Recipients in ICU with Sepsis or Respiratory Failure
In kidney transplant patients who are in the ICU for septic shock or severe respiratory failure, the study will test a targeted approach to adjust immunosuppressive therapy and provide education to support safer care.
-
Single versus dual antiplatelet therapy after drug-coated balloon angioplasty in elderly or high-bleeding-risk patients
This study tests whether taking one antiplatelet medicine is as safe and causes less bleeding than taking two medicines for people aged 75 or older, or adults at high bleeding risk, after drug-coated balloon angioplasty for coronary artery disease.
Related topics
Quick answers
How many Immunosuppressive Agents clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in France (1 trial), Italy (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.